Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc reports positive phase 3 Study outcome Of XALKORI (crizotinib) compared to chemotherapy in previously untreated patients with ALK-positive advanced non-small cell lung cancer


Tuesday, 25 Mar 2014 08:30am EDT 

Pfizer Inc:PROFILE 1014, Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor XALKORI(crizotinib).Met its primary objective of significantly prolonging progression-free survival (PFS) in previously untreated patients with ALK-positive advanced non-squamous non-small cell lung cancer (NSCLC) when compared to standard platinum-based chemotherapy regimens.PROFILE 1014 is second positive global Phase 3 study that evaluated XALKORI against chemotherapy, a standard of care for patients with advanced NSCLC.No unexpected safety issues were identified in the PROFILE 1014 study. 

Company Quote

40.55
0.22 +0.55%
28 Jul 2014